Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294058 · ClinicalTrials.gov registry record · Phase 3
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,346
- Enrollment target
NCT02294058: Completed Phase 3 study, sponsored by Celgene.
NCT02294058 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,346 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02294058, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,346 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Primary Outcome
The relapse rate was based on confirmed relapses. A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for \> 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall
Interventions
- DRUG Ozanimod
- DRUG Interferon beta-1a
- DRUG Placebo to ozanimod
- DRUG Placebo to interferon beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,346 participants |
| Start Date | 2014-12-03 |
| Est. Completion | 2016-12-22 |
| Phase | Phase 3 |
What the finished NCT02294058 record still lists
NCT02294058 is an interventional study that assigns participants to a tested intervention. Its 1,346 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% higher).
The record links to 0 conditions, and to 4 interventions - of which Ozanimod is the first listed.
NCT02294058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02294058 about?
NCT02294058 is a clinical study titled "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)". The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
What is the current status of trial NCT02294058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,346 participants. The study started on 2014-12-03. Estimated completion is 2016-12-22.
What interventions are being tested in trial NCT02294058?
The interventions under investigation include: Ozanimod (DRUG), Interferon beta-1a (DRUG), Placebo to ozanimod (DRUG), Placebo to interferon beta-1a (DRUG).
Who is sponsoring clinical trial NCT02294058?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02294058's enrollment target sits among peer trials
1,346 182nd of 2000 higher than 1,819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI